Education
About Us
Working with TipRanks
Follow Us
Medical Properties Trust (MPT)
NYSE:MPT
Top Page
Medical Properties Trust
(NYSE:MPT)
Select Model
Select Model
Rating:45Neutral
Price Target:
$5.00
â–²(4.17% Upside)
Action:ReiteratedDate:03/12/26
The score is primarily constrained by weak financial quality—ongoing losses, negative shareholder returns, and especially the latest TTM showing no operating/free cash flow. Technicals also remain bearish with the stock below key moving averages, despite oversold signals. Offsetting factors are a high dividend yield and a relatively constructive earnings call focused on 2026 stabilization and improving tenant/operator performance, though refinancing and cash-collection risks remain.
Positive Factors
Improved Portfolio Coverage
Higher portfolio EBITDARM coverage (2.6x) signals improved operator profitability across core assets, reducing default risk and supporting contractual rent collection. Over months this enhances cash predictability, lowers impairment risk, and strengthens the REIT's ability to stabilize distributions and refinance maturities.
Long-term Lease Restructuring
A 20-year master lease and restructuring with a major tenant secures long-dated, contracted cash flows and reduces rollover risk. The structural tenor and one-time payment improve near-term liquidity while locking in occupancy and aligning incentives, supporting durable rent coverage and credit stability over multiple years.
Rent Ramp & Growth Targets
Clear rent-ramp targets and new long-term leases create a multi-year revenue growth trajectory. Achieving $1B annualized cash rent and stabilized NOR cash flows materially increases recurring income, supporting FFO stabilization and reducing reliance on one-off proceeds as the portfolio moves toward normalized contractual collections.
Negative Factors
Weak Cash Generation
TTM operating cash flow and free cash flow at zero indicate materially weakened internal liquidity. Over months this constrains capital for dividends, capex, and tenant support, forcing reliance on capital markets or asset sales and amplifying refinancing risk around upcoming maturities if collections don't improve.
Elevated Leverage
Historically high debt ratios leave limited balance-sheet flexibility. Even with some reported debt reduction, sustained negative returns and periodic losses increase sensitivity to interest rates and refinancing costs, raising the structural risk that future earnings volatility could pressure covenant headroom and capital strategy.
Refinancing & Collection Risks
Concentrated near-term maturities combined with ongoing tenant recovery items (Prospect impairments, HSA collections) create structural funding pressure. Over the next 2–6 months these factors increase dependence on successful refinancing or asset sales, and weak collections could tighten liquidity and raise financing costs.
Medical Properties Trust (MPT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.87B
Dividend Yield6.57%
Average Volume (3M)6.99M
Price to Earnings (P/E)―
Beta (1Y)0.88
Revenue Growth45.56%
EPS Growth73.44%
CountryUS
Employees118
SectorReal Estate
Sector Strength53
IndustryREIT - Industrial
Share Statistics
EPS (TTM)0.03
Shares Outstanding597,700,000
10 Day Avg. Volume7,705,987
30 Day Avg. Volume6,992,667
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)0.65
Price to Sales (P/S)3.09
P/FCF Ratio13.02
Enterprise Value/Market Cap8.15
Enterprise Value/Revenue24.07
Enterprise Value/Gross Profit25.00
Enterprise Value/Ebitda23.01
Forecast
1Y Price Target
$6.67Price Target Upside38.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)0.1
Revenue Forecast (FY)$994.39M
Medical Properties Trust Business Overview & Revenue Model
Company DescriptionMedical Properties Trust, Inc. is a self-advised real estate investment trust. It engages in the investment, acquisition, and development of net-leased healthcare facilities. Its property portfolio includes rehabilitation hospitals, long-term acute care hospitals, ambulatory surgery centers, hospitals for women and children, regional and community hospitals, medical office buildings, and other single-discipline facilities. The company was founded by Edward K. Aldag Jr., R. Steven Hamner, Emmett E. McLean, and William Gilliard McKenzie in 2003 and is headquartered in Birmingham, AL.
How the Company Makes MoneyMPT primarily makes money by collecting contractual rent from hospital operators under long-term leases on the healthcare properties it owns. Its core revenue stream is lease income (often structured as triple-net arrangements where tenants are generally responsible for property-level operating costs such as taxes, insurance, and maintenance), which is designed to produce predictable, recurring cash flows. In addition to base rent, leases may include contractual escalators (periodic increases tied to fixed amounts and/or inflation indices, depending on the lease), which can increase rental revenue over time. MPT can also generate income from financing-related activities connected to its real estate transactions (e.g., interest income when it provides loans to operators or affiliates as part of acquisition/leaseback or recapitalization structures) and from property dispositions (gains or losses on the sale of real estate assets), though these are typically less recurring than rent. Key factors influencing earnings include tenant/operator financial health and rent coverage, property occupancy and lease renewals, interest rates and access to capital (which affect borrowing costs and acquisition economics), and portfolio concentration with major operators. Specific partnership terms or operator-by-operator arrangements beyond these general mechanisms are null.
Medical Properties Trust Earnings Call Summary
Earnings Call Date:Feb 19, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 23, 2026
Earnings Call Sentiment Positive
The call conveyed multiple operational and financial positives — meaningful year-over-year EBITDARM gains across core segments (general acute and rehab), strategic lease restructurings (Vibra), selective accretive acquisitions, progress on Prospect recoveries, and clear targets for cash rent and rent ramp-through 2026. Offsetting these positives are isolated but material challenges: behavioral health softness (U.K. funding and U.S. labor pressures), lingering Prospect-related impairments and remaining collections, HSA cash-collection shortfalls (with remediation tied to a Q2 EMR implementation), and several near-term debt maturities that require refinancing actions. Overall, management presented confidence in portfolio resilience and multiple tactical options to address capital needs.Q4-2025 Updates
Positive Updates
Improved Portfolio Coverage and Strong Operator Performance
Total portfolio EBITDARM coverage increased year-over-year to 2.6x. General acute operators delivered more than $130 million of incremental EBITDARM versus the same quarter last year.
Post-Acute Portfolio Momentum
Post-acute care operators reported a $50 million year-over-year EBITDARM increase, highlighted by Ernest Health (+15% EBITDARM), Vibra (+28% EBITDARM) and Median (reported +8% in one section and >20% in Germany in another), demonstrating strong rehab performance and higher occupancies (Median Germany occupancy ~90%).
Vibra Restructuring and Master Lease
Completed a Vibra restructuring and signed a new 20-year master lease; collected approximately $18 million one-time payment as part of the transaction. Management noted Vibra refinanced its debt and is a significantly stronger tenant post-transaction.
Selective Acquisitions with Attractive Economics
Acquired a high-performing post-acute facility in California for ~ $32 million (described as strong cap rate) and a European post-acute facility for EUR 23 million; invested roughly $60 million in two well-performing post-acute rehab facilities to add to master leases.
Lease Wins and Rent Ramp Expectations
Entered a 15-year lease with NOR Health Systems expected to reach stabilized annual cash rent of $45 million by December 2026; management expects recently transitioned tenants to reach 100% contractual rent by end of 2026 and targets over $1 billion in annualized cash rent by year-end 2026.
Normalized FFO and One-Time Cash Benefits
Reported normalized FFO of $0.18 per share for Q4 and $0.58 per share for full year 2025. Management noted normalized FFO was approximately $0.03–$0.04 higher in the quarter due to cash receipts including Vibra restructuring and a $4 million HSA payment.
Cash Proceeds from Prospect Process
Received approximately $70 million of net proceeds from the Prospect bankruptcy in the quarter, with an expected remaining collection of ~$60 million in 2026 as the process concludes.
Balance Sheet Actions and Capital Markets Execution
Announced a $150 million share repurchase authorization and repurchased just under 1% of market cap by year-end; secured financing market access noted (prior secured notes trading at premiums implying ~5% rates), and management articulated multiple refinancing/deleveraging options for upcoming maturities.
Operational Wins — Refinancing and Partnerships
Ernest Health delivered double-digit EBITDARM growth and refinanced its 2026 term loan and revolver in Q4 extending maturities to 2030 and compressing its rates. Swiss Medical Network reported solid hospital EBITDARM growth and announced a clinical collaboration with the Mayo Clinic.
Negative Updates
Behavioral Health Softness
Behavioral health portfolio was down slightly year-over-year attributable to volume headwinds in the U.K. (NHS budget constraints impacting referrals) and labor cost pressures in the U.S.; Priory is adjusting service lines in response to referral and funding shifts.
HSA Cash Collections and Operational Transition
HSA showed only modest improvements in collections; while coverage on a fully ramped rent basis is cited around 1x, cash collections are lagging. Management expects the MEDITECH EMR implementation in Q2 2026 to support revenue cycle improvements and full stand-alone operations.
Prospect-Related Impairments and Ongoing Recovery
Recorded approximately $34 million of impairment charges in the quarter, the majority related to Prospect. Although $70 million net proceeds were received this quarter, ~$60 million remains to be collected in 2026 and certain bankruptcy-related transactions and DIP financing remain to be finalized.
Revenue Recognition and Cash-Basis Accounting for Key Tenants
Several significant tenants (including historically Vibra and some transition tenants) have been accounted for on a cash-received basis, which suppresses recognized rental revenue until collections ramp and creates near-term visibility constraints.
Near-Term Debt Maturities and Refinancing Needs
Material upcoming maturities include a EUR 500 million unsecured note maturing in October 2026 (at 0.99% today), a bank revolver and $200 million term loan maturing in June 2027 (subject to extension), and $1.4 billion unsecured notes maturing October 2027 — creating refinancing needs despite multiple available options.
Operational & Staffing Pressures in U.S. Behavioral Segment
U.S. behavioral facilities face labor shortages and cost pressures that are constraining volume and margin recovery despite demand, limiting short-term earnings improvements in that segment.
Company Guidance
Management reiterated that 2026 is expected to be a year of stabilization and rising cash rents, with a target of exceeding $1.0 billion in annualized cash rent by year-end 2026 and recently-transitioned tenants expected to reach 100% contractual rent by that time; portfolio EBITDARM coverage rose to 2.6x, driven by a >$130 million YoY increase at general acute operators and a $50 million YoY increase at post‑acute operators (Ernest +15%, Vibra +28%, Median +8%), while Median in Germany posted its strongest quarter with >20% QoQ EBITDARM growth and 90% occupancy. Key transaction and cash metrics cited include a new 20‑year master lease with Vibra and an $18 million one‑time cash payment from Vibra, acquisitions of a California post‑acute facility for ~$32 million and a European post‑acute facility for EUR 23 million, sale of 6 smaller properties, a new 15‑year NOR lease expected to stabilize at $45 million annual cash rent in December 2026, ~$70 million of Prospect bankruptcy proceeds received in Q4 with ~$60 million remaining expected in 2026, and a Q4 normalized FFO of $0.18/sh ($0.58/sh full year) (benefiting ~$0.03–$0.04/sh from one‑time cash receipts) offset by ~ $34 million of impairments. On the balance sheet, management highlighted near‑term maturities (EUR 500 million unsecured notes due Oct at 0.99%, bank revolver and $200 million term loan maturing June 2027 after presumed extension, and $1.4 billion unsecured notes due Oct 2027), recent $2.5 billion secured note issuances and 10‑year German financing trading around mid‑5% levels, a $150 million repurchase authorization (used to buy back just under 1% of market cap to date, ~ $25 million repurchased this quarter), and selective $60 million of accretive property investments.Medical Properties Trust Financial Statement Overview
Summary
Despite modest TTM revenue growth and strong reported operating margins, results are pressured by persistent net losses (TTM net margin ~-20.4%), negative ROE in 2023/2024/TTM, and a sharp deterioration in cash generation (TTM operating cash flow and free cash flow reported at 0). Historically elevated leverage remains a risk, only partially offset by the recent reduction in reported total debt.Income Statement
TTM (Trailing-Twelve-Months) revenue is modestly higher (+3.7%), and operating profitability remains strong on the surface (gross margin ~55.7%, EBITDA margin ~60.6%, EBIT margin ~33.2%). However, the company is still loss-making in TTM (net margin ~-20.4%) and the annual results show significant earnings volatility, including very large net losses in 2023 and 2024 after solid profitability in 2020–2022. Overall, the core earning profile looks pressured and less predictable despite resilient top-line trends.34
Negative
Balance Sheet
Leverage has historically been elevated (debt-to-equity ~1.23–1.86 in 2020–2024), and profitability to shareholders has deteriorated with negative returns on equity in 2023, 2024, and TTM. A key positive is that TTM shows sharply lower reported total debt versus prior years, but equity remains large and recent losses still weigh on balance-sheet quality. Net result: leverage and negative shareholder returns are material risks, partially offset by the recent improvement in reported debt levels.42
Neutral
Cash Flow
Cash generation weakened materially: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are reported at 0, implying a step-down from positive operating and free cash flow in 2023–2024. Historically, operating cash flow was solid (2020–2024), but free cash flow has been volatile, including sizable deficits in 2020 and 2022. With the latest TTM showing no operating cash inflow and no free cash flow, liquidity and funding flexibility appear challenged.18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 972.02M | 995.55M | 871.80M | 1.54B | 1.54B |
| Gross Profit | 935.61M | 968.29M | 830.23M | 1.50B | 1.51B |
| EBITDA | 812.59M | 840.60M | 697.41M | 1.35B | 1.37B |
| Net Income | -277.05M | -2.41B | -556.48M | 902.60M | 656.02M |
Balance Sheet | |||||
| Total Assets | 15.00B | 14.29B | 18.30B | 19.66B | 20.52B |
| Cash, Cash Equivalents and Short-Term Investments | 540.86M | 332.33M | 250.02M | 235.67M | 459.23M |
| Total Debt | 9.83B | 8.98B | 10.22B | 10.41B | 11.37B |
| Total Liabilities | 10.39B | 9.46B | 10.67B | 11.06B | 12.07B |
| Stockholders Equity | 4.61B | 4.83B | 7.63B | 8.59B | 8.44B |
Cash Flow | |||||
| Free Cash Flow | 230.77M | 245.48M | 505.79M | -801.35M | 746.11M |
| Operating Cash Flow | 230.77M | 245.48M | 505.79M | 739.01M | 811.66M |
| Investing Cash Flow | -264.74M | 1.32B | 517.56M | 396.06M | -3.86B |
| Financing Cash Flow | 228.08M | -1.48B | -1.02B | -1.34B | 2.95B |
Medical Properties Trust Technical Analysis
Negative
4.80
Price Trends
5.24
Negative
5.13
Negative
4.74
Positive
Market Momentum
-0.14
Positive
35.93
Neutral
6.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MPT, the sentiment is Negative. The current price of 4.8 is below the 20-day moving average (MA) of 5.33, below the 50-day MA of 5.24, and above the 200-day MA of 4.74, indicating a neutral trend. The MACD of -0.14 indicates Positive momentum. The RSI at 35.93 is Neutral, neither overbought nor oversold. The STOCH value of 6.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MPT.
Medical Properties Trust Risk Analysis
Medical Properties Trust disclosed 53 risk factors in its most recent earnings report. Medical Properties Trust reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Medical Properties Trust Peers Comparison
UnderperformOutperform
Sector (65)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $8.91B | 18.09 | 8.99% | 3.56% | 59.25% | 88.37% | |
70 Outperform | $4.13B | 25.18 | 9.63% | 4.73% | 8.04% | 9.20% | |
70 Outperform | $5.20B | 29.37 | 5.63% | 6.47% | 8.12% | 75.95% | |
69 Neutral | $1.88B | 13.47 | 11.94% | 6.70% | 11.89% | -68.41% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
54 Neutral | $1.73B | -13.73 | -15.98% | 0.80% | 4.10% | 8.96% | |
45 Neutral | $2.87B | -10.84 | -5.88% | 6.57% | 45.56% | 73.44% |
* Real Estate Sector Average
MPT
Medical Properties Trust
4.80
-0.77
-13.85%
LTC
LTC Properties
38.75
5.57
16.80%
NHI
National Health Investors
85.20
12.39
17.02%
SBRA
Sabra Healthcare REIT
20.63
4.12
24.97%
DHC
Diversified Healthcare Trust
7.13
4.44
165.25%
CTRE
CareTrust REIT
39.91
11.71
41.53%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.